SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ADVENTRX Pharmaceuticals Inc (Anx)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: estatemakr who wrote (101)5/22/2007 5:14:55 PM
From: Keith FeralRead Replies (1) of 418
 
You make perfectly logical suggestions, but that is rarely the way that the world works. I think 2X to 3X gets the company close to what I see happening to the stock price after the data is released this summer. I fully expect the value of the company to exceed $1 billion when they announce data and partnerships. Hell, they have their first approval coming out this summer too for vinorelbine.

The world needs a safer and cheaper way to address anemia in post chemo. It's grossly unfair to consumers to be paying $10,000 per treatment of epogen, which does zilch to increase the efficacy of chemo drugs. Cofactor is the biggest drug for chemo, as it doubles the first line response rate against tumor growth and eliminates all of the hematological side effects. It will be exciting to reconfirm the phase 2 results with the new phase 2 b data this summer.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News